Glibornuride

Research use only, not for human use.

Glibornuride is a blocker of ATP-sensitive K+ channel(pKi: 5.75). Glibornuride inhibits high affinity [3H]-glibenclamide binding with the potencies expected from their K+ channel activity.

Glibornuride is a blocker of ATP-sensitive K+ channel(pKi: 5.75). Glibornuride inhibits high affinity [3H]-glibenclamide binding with the potencies expected from their K+ channel activity.(In Vivo):The diabetic group, given Glibornuride(5mg/kg), blood glucose, serum alkaline phosphatase activity, serum sialic acid, uric acid, potassium, and liver NEG levels decreased, but liver LPO, GSH, serum sodium levels, and body weight increased.

——

Animal Model:6-6.5-month-old male Swiss Albino rats, weighing 150-200 g Dosage:5 mg/kg Administration:Given by gavage, daily for 28 days Result:Administration for 28 days caused an increase in body weights in the diabetic groups. Treatment for 28 days decreased the serum uric acid levels in diabetic rats.

——

Cell Cycle/DNA Damage

Potassium Channel

——

——

——

26944-48-9

366.48

C18H26N2O4S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (682.17 mM)

[H][C@@]12CC[C@@](C)([C@@H](O)[C@H]1NC(=O)NS(=O)(=O)c1ccc(C)cc1)C2(C)C

——

(-20℃)

With Ice Pack

≥ 2 years